WikiMD is the world's largest medical encyclopedia with
13,858 pages, 4,142,531 edits & 40,172,680 views.
Acalabrutinib and breast feeding
No information is available on the clinical use of acalabrutinib during breastfeeding. Because acalabrutinib is over 97% bound to plasma proteins, and the half-life of the drug and metabolite are less than 7 hours, the amount in milk is likely to be low. However, the protein binding of the active metabolite is not known and the manufacturer recommends that breastfeeding be discontinued during acalabrutinib therapy and for at least 2 weeks after the final dose.
Latest research
Up to date info
Alternative drugs - Acalabrutinib and breast feeding
Suggested alternatives on Acalabrutinib and breast feeding, when available and appropriate.
Breast feeding and drugs
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
External links
This WikiMD article Acalabrutinib and breast feeding is a stub. If you are familiar with the topic Acalabrutinib and breast feeding, you can help us. Paid editors welcome!
Acalabrutinib and breast feeding is part of WikiMD's free ^articles!
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
 Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available |
